De novo design of antiviral and antibacterial peptides with varying loop structures

Guangshun Wang, Karen W. Buckheit, Biswajit Mishra, Tamara Lushnikova, Robert W. Buckheit

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although the rate of new HIV infections has been declining, AIDS continues to be one of the leading causes of death worldwide. The lack of an effective HIV vaccine makes it necessary to develop alternative strategies, such as the development of topical microbicides, to prevent transmission. Antimicrobial peptides represent promising microbicide candidates. Previously, we succeeded in enhancing the anti-HIV activities of several peptides that form helical structures based on the bioinformatic results learned from the antimicrobial peptide database. This study showed that Lys-to-Arg alterations also improved the HIV inhibitory activity of thanatin which is known to form a β-hairpin structure. Using a previously reported de novo designed HIV inhibitory peptide GLR-19 as the starting template, loop structures of varying sizes were generated by restraining a disulfide bond at different positions. The thanatin-mimicking constructs are referred to as GLRC peptides since they are composed of only four amino acid residues G, L, R, and C. While GLRC-2, the peptide with a medium-sized loop structure, was most potent against HIV-1 and HSV-2, GLRC-3, with the small loop structure, was most potent against Escherichia coli K12. Thus, the efficacy of the GLRC peptides is microbe dependent. Further terminal sequence truncation of GLRC-2 reduced antimicrobial activity against both viruses and bacteria. It appears that the high antiviral potency of GLRC-2 is related to high hydrophobicity, although a wide-range correlation is lacking. In addition, GLRC-2, which is more active against viruses, is also more resistant to the action of chymotrypsin. Therefore, GLRC-2, a novel peptide that acquired not only higher stability but also higher anti-HIV activity than the GLR-19 template, serves as the starting point for additional rounds of peptide engineering.

Original languageEnglish (US)
JournalJournal of AIDS and Clinical Research
Volume3
Issue numberSPL ISSUE2
DOIs
StatePublished - Dec 1 2012

Fingerprint

Antiviral Agents
Peptides
HIV
Viruses
Escherichia coli K12
AIDS Vaccines
Local Anti-Infective Agents
Human Herpesvirus 2
Chymotrypsin
Anti-Infective Agents
Computational Biology
Hydrophobic and Hydrophilic Interactions
Disulfides
HIV Infections
HIV-1
Cause of Death
Acquired Immunodeficiency Syndrome
Databases
Bacteria
Amino Acids

Keywords

  • Antimicrobial peptides
  • HIV-1
  • Microbicides
  • Peptide stability

ASJC Scopus subject areas

  • Immunology
  • Dermatology
  • Infectious Diseases
  • Virology

Cite this

De novo design of antiviral and antibacterial peptides with varying loop structures. / Wang, Guangshun; Buckheit, Karen W.; Mishra, Biswajit; Lushnikova, Tamara; Buckheit, Robert W.

In: Journal of AIDS and Clinical Research, Vol. 3, No. SPL ISSUE2, 01.12.2012.

Research output: Contribution to journalArticle

Wang, Guangshun ; Buckheit, Karen W. ; Mishra, Biswajit ; Lushnikova, Tamara ; Buckheit, Robert W. / De novo design of antiviral and antibacterial peptides with varying loop structures. In: Journal of AIDS and Clinical Research. 2012 ; Vol. 3, No. SPL ISSUE2.
@article{0055f13de2cd4c19b2195c47d807ece9,
title = "De novo design of antiviral and antibacterial peptides with varying loop structures",
abstract = "Although the rate of new HIV infections has been declining, AIDS continues to be one of the leading causes of death worldwide. The lack of an effective HIV vaccine makes it necessary to develop alternative strategies, such as the development of topical microbicides, to prevent transmission. Antimicrobial peptides represent promising microbicide candidates. Previously, we succeeded in enhancing the anti-HIV activities of several peptides that form helical structures based on the bioinformatic results learned from the antimicrobial peptide database. This study showed that Lys-to-Arg alterations also improved the HIV inhibitory activity of thanatin which is known to form a β-hairpin structure. Using a previously reported de novo designed HIV inhibitory peptide GLR-19 as the starting template, loop structures of varying sizes were generated by restraining a disulfide bond at different positions. The thanatin-mimicking constructs are referred to as GLRC peptides since they are composed of only four amino acid residues G, L, R, and C. While GLRC-2, the peptide with a medium-sized loop structure, was most potent against HIV-1 and HSV-2, GLRC-3, with the small loop structure, was most potent against Escherichia coli K12. Thus, the efficacy of the GLRC peptides is microbe dependent. Further terminal sequence truncation of GLRC-2 reduced antimicrobial activity against both viruses and bacteria. It appears that the high antiviral potency of GLRC-2 is related to high hydrophobicity, although a wide-range correlation is lacking. In addition, GLRC-2, which is more active against viruses, is also more resistant to the action of chymotrypsin. Therefore, GLRC-2, a novel peptide that acquired not only higher stability but also higher anti-HIV activity than the GLR-19 template, serves as the starting point for additional rounds of peptide engineering.",
keywords = "Antimicrobial peptides, HIV-1, Microbicides, Peptide stability",
author = "Guangshun Wang and Buckheit, {Karen W.} and Biswajit Mishra and Tamara Lushnikova and Buckheit, {Robert W.}",
year = "2012",
month = "12",
day = "1",
doi = "10.4172/2155-6113.S2-003",
language = "English (US)",
volume = "3",
journal = "Journal of AIDS and Clinical Research",
issn = "2155-6113",
publisher = "OMICS Publishing Group",
number = "SPL ISSUE2",

}

TY - JOUR

T1 - De novo design of antiviral and antibacterial peptides with varying loop structures

AU - Wang, Guangshun

AU - Buckheit, Karen W.

AU - Mishra, Biswajit

AU - Lushnikova, Tamara

AU - Buckheit, Robert W.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Although the rate of new HIV infections has been declining, AIDS continues to be one of the leading causes of death worldwide. The lack of an effective HIV vaccine makes it necessary to develop alternative strategies, such as the development of topical microbicides, to prevent transmission. Antimicrobial peptides represent promising microbicide candidates. Previously, we succeeded in enhancing the anti-HIV activities of several peptides that form helical structures based on the bioinformatic results learned from the antimicrobial peptide database. This study showed that Lys-to-Arg alterations also improved the HIV inhibitory activity of thanatin which is known to form a β-hairpin structure. Using a previously reported de novo designed HIV inhibitory peptide GLR-19 as the starting template, loop structures of varying sizes were generated by restraining a disulfide bond at different positions. The thanatin-mimicking constructs are referred to as GLRC peptides since they are composed of only four amino acid residues G, L, R, and C. While GLRC-2, the peptide with a medium-sized loop structure, was most potent against HIV-1 and HSV-2, GLRC-3, with the small loop structure, was most potent against Escherichia coli K12. Thus, the efficacy of the GLRC peptides is microbe dependent. Further terminal sequence truncation of GLRC-2 reduced antimicrobial activity against both viruses and bacteria. It appears that the high antiviral potency of GLRC-2 is related to high hydrophobicity, although a wide-range correlation is lacking. In addition, GLRC-2, which is more active against viruses, is also more resistant to the action of chymotrypsin. Therefore, GLRC-2, a novel peptide that acquired not only higher stability but also higher anti-HIV activity than the GLR-19 template, serves as the starting point for additional rounds of peptide engineering.

AB - Although the rate of new HIV infections has been declining, AIDS continues to be one of the leading causes of death worldwide. The lack of an effective HIV vaccine makes it necessary to develop alternative strategies, such as the development of topical microbicides, to prevent transmission. Antimicrobial peptides represent promising microbicide candidates. Previously, we succeeded in enhancing the anti-HIV activities of several peptides that form helical structures based on the bioinformatic results learned from the antimicrobial peptide database. This study showed that Lys-to-Arg alterations also improved the HIV inhibitory activity of thanatin which is known to form a β-hairpin structure. Using a previously reported de novo designed HIV inhibitory peptide GLR-19 as the starting template, loop structures of varying sizes were generated by restraining a disulfide bond at different positions. The thanatin-mimicking constructs are referred to as GLRC peptides since they are composed of only four amino acid residues G, L, R, and C. While GLRC-2, the peptide with a medium-sized loop structure, was most potent against HIV-1 and HSV-2, GLRC-3, with the small loop structure, was most potent against Escherichia coli K12. Thus, the efficacy of the GLRC peptides is microbe dependent. Further terminal sequence truncation of GLRC-2 reduced antimicrobial activity against both viruses and bacteria. It appears that the high antiviral potency of GLRC-2 is related to high hydrophobicity, although a wide-range correlation is lacking. In addition, GLRC-2, which is more active against viruses, is also more resistant to the action of chymotrypsin. Therefore, GLRC-2, a novel peptide that acquired not only higher stability but also higher anti-HIV activity than the GLR-19 template, serves as the starting point for additional rounds of peptide engineering.

KW - Antimicrobial peptides

KW - HIV-1

KW - Microbicides

KW - Peptide stability

UR - http://www.scopus.com/inward/record.url?scp=84879811817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879811817&partnerID=8YFLogxK

U2 - 10.4172/2155-6113.S2-003

DO - 10.4172/2155-6113.S2-003

M3 - Article

VL - 3

JO - Journal of AIDS and Clinical Research

JF - Journal of AIDS and Clinical Research

SN - 2155-6113

IS - SPL ISSUE2

ER -